Extracellular vesicles and microRNAs in cancer progression
Advances in clinical chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer
Farah Abul Rub,
Naseel Moursy,
Nouf Alhedeithy
и другие.
Biosensors,
Год журнала:
2025,
Номер
15(4), С. 203 - 203
Опубликована: Март 21, 2025
Ovarian
cancer
(OC)
is
one
of
the
leading
causes
gynecological
cancer-related
death
worldwide.
Late
diagnosis
at
advanced
stages
OC
reason
for
a
higher
mortality
rate.
Earlier
and
proper
treatment
are
important
improving
prognosis
patients.
Biosensors
offer
accurate,
low-cost,
rapid,
user-friendly
devices
that
can
be
employed
detection
OC-specific
biomarkers
in
early
stage.
Therefore,
it
to
consider
potential
biological
fluids
confirm
prognosis.
Out
many
biomarkers,
most
commonly
tested
clinically
antigen
125
(CA-125).
However,
CA-125
considered
poor
biomarker
diagnosis.
Several
biosensing
methods
were
developed
sensitive
quantitative
each
biomarker.
In
abnormal
expression
patients,
nucleic
acids,
enzymes,
cells,
exosomes
used
as
target
construction
biosensors.
This
review
focuses
on
development
various
using
multiple
methods.
Here,
we
describe
origin
significance
OC-associated
working
principle
biosensors,
classification
biosensors
based
their
recognition
elements
signal
transducers.
The
modes
sensitivity
sensors
discussed.
Finally,
challenges
fabrication,
obstacles
clinical
application,
future
prospects
Язык: Английский
Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies
Journal of Ovarian Research,
Год журнала:
2025,
Номер
18(1)
Опубликована: Апрель 5, 2025
Ovarian
Cancer
(OC)
is
recognized
as
the
most
lethal
gynecologic
malignancy,
characterized
by
numerous
genetic
mutations
that
trigger
uncontrolled
cellular
growth
and
replication.
Emerging
evidence
suggests
non-coding
RNAs
including
miRNAs
lncRNAs
significantly
influence
OC
through
their
multiple
roles
tumor
initiation,
progression,
metastasis,
immune
evasion,
chemoresistance,
making
them
promising
diagnostic
markers
therapeutic
targets.
The
primary
approach
to
treating
typically
involves
cytoreductive
surgery
followed
chemotherapy.
However,
chemotherapeutic
agents,
particularly
anthracyclines
such
doxorubicin
(DOX),
are
known
for
cardiotoxic
effects,
which
can
range
from
acute
chronic,
potentially
leading
heart
failure
death.
To
enhance
overall
treatment
response
minimize
cardiotoxicity,
alternative
strategies
have
been
explored.
These
include
use
of
liposomal
(DOXIL)
a
substitute
DOX,
various
radiotherapies,
immunotherapies,
co-administration
angiotensin-converting
enzyme
inhibitors
and/or
beta-blockers.
Phosphodiesterase-5
(PDE5i)
also
demonstrated
efficacy
in
reducing
cardiotoxicity
linked
cancer
treatments
promoting
apoptosis
cells
across
types.
Although
there
no
current
clinical
trial
directly
examining
impact
PDE5i
on
OC,
however
emerging
therapies
Withaferin
A,
PARP
inhibitors,
nanoparticle
combination
therapy
show
promise.
Additional
research
essential
develop
both
effective
against
less
harmful
heart.
Язык: Английский
Advancing ovarian cancer management: Role of nucleic acid biomarkers and novel therapeutic approaches
Gene Reports,
Год журнала:
2025,
Номер
unknown, С. 102241 - 102241
Опубликована: Май 1, 2025
Язык: Английский
Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma
Cancers,
Год журнала:
2024,
Номер
16(23), С. 3969 - 3969
Опубликована: Ноя. 26, 2024
Ovarian
carcinoma
(OC)
has
an
unfavorable
prognosis
due
to
lack
of
screening
and
asymptomatic
course.
New
diagnostic
methods
are
being
sought
enable
earlier
diagnosis
this
condition.
The
purpose
study
was
determine
the
utility
collagenases
(MMP-1,
MMP-8
MMP-13)
in
OC
compared
HE4
CA125
ROMA.
Язык: Английский
Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(22), С. 11927 - 11927
Опубликована: Ноя. 6, 2024
Epithelial
ovarian
cancer
(EOC)
is
the
most
lethal
gynecological
malignancy
worldwide.
Due
to
its
nonspecific
symptoms
and
unreliable
screening
tools,
EOC
not
diagnosed
at
an
early
stage
in
cases.
Unfortunately,
despite
achieving
initial
remission
after
debulking
surgery
platinum-based
chemotherapy,
patients
experience
recurrence
of
disease.
The
limited
therapy
approaches
have
encouraged
scientists
search
for
new
detection
therapeutic
strategies.
In
this
review,
we
discuss
role
folate
receptor
alpha
(FRα)
development
potential
application
as
a
biomarker
molecular
target
designing
treatment
methods.
We
summarize
mechanisms
action
various
strategies
based
on
FRα,
including
MABs
(monoclonal
antibodies),
ADCs
(antibody-drug
conjugates),
FDCs
(folate-drug
SMDCs
(small
molecule-drug
vaccines,
CAR-T
(chimeric
antigen
T)
cells,
present
significant
clinical
trials
some
FRα-based
drugs.
Furthermore,
pros
cons
different
FR-based
therapies,
highlighting
mirvetuximab
soravtansine
(MIRV)
currently
promising
EOC-targeting
drug.
Язык: Английский